Skip to content

Author

M. Sormani

We have 6 of 725 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Macro- and microstructural changes in the upper cervical spinal cord and their clinical correlates in multiple sclerosis

Spinal cord (SC) damage is central to multiple sclerosis (MS) progression but remains difficult to quantify with conventional magnetic resonance imaging (MRI). To characterize upper cervical SC pathology using quantitative MRI (qMRI) and assess longitudinal changes and predictors of clinical progression and...

Kornelius Kaim, M. Ocampo-Pineda, C. Tsagkas et al. · 0 citations
Review Open access Aug 2026

Central vein sign and paramagnetic rim lesions in pediatric-onset multiple sclerosis: a systematic review and meta-analysis

Susceptibility-based MRI biomarkers, including paramagnetic rim lesions (PRLs) and central vein sign (CVS), were incorporated into the 2024 McDonald criteria because they improve diagnostic specificity in adult-onset MS; however, their role in pediatric-onset MS (POMS) remains incompletely defined. To synthesize curren...

Anna de Mauro, Rosa Cortese, Giulia Fadda et al. · 0 citations
Clinical trial Open access Aug 2026

Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells.

Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial...

Andreas Lutterotti, Thomas Ludersdorfer, M. Docampo et al. · 1 citation
Aug 2026

Rethinking multiple sclerosis therapy beyond clinical phenotypes.

Sormani et al. argue that multiple sclerosis should be viewed as a biological continuum rather than distinct clinical forms. Evidence from recent trials suggests that therapies targeting shared biological mechanisms can slow disability progression across the disease spectrum, supporting a shift away from traditional cl...

M. Sormani, Heinz Wiendl, X. Montalban et al. · 0 citations
Open access Sep 2026

T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation

Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...

L. Gualco, N. Montobbio, M. Losa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.